149 related articles for article (PubMed ID: 38534768)
1. Editorial for the Special Issue "Molecular Biology in Targeted Radionuclide Therapy Radiopharmaceutical Design".
Aprile C; Geatti O; Canziani L; Lodola L
Curr Issues Mol Biol; 2024 Mar; 46(3):2398-2401. PubMed ID: 38534768
[TBL] [Abstract][Full Text] [Related]
2.
Li M; Sagastume EA; Lee D; McAlister D; DeGraffenreid AJ; Olewine KR; Graves S; Copping R; Mirzadeh S; Zimmerman BE; Larsen RH; Johnson FL; Schultz MK
Curr Med Chem; 2020; 27(41):7003-7031. PubMed ID: 32720598
[TBL] [Abstract][Full Text] [Related]
3. Combining Targeted Radionuclide Therapy and Immune Checkpoint Inhibition for Cancer Treatment.
Kleinendorst SC; Oosterwijk E; Bussink J; Westdorp H; Konijnenberg MW; Heskamp S
Clin Cancer Res; 2022 Sep; 28(17):3652-3657. PubMed ID: 35471557
[TBL] [Abstract][Full Text] [Related]
4. A Mathematical Modeling Approach for Targeted Radionuclide and Chimeric Antigen Receptor T Cell Combination Therapy.
Adhikarla V; Awuah D; Brummer AB; Caserta E; Krishnan A; Pichiorri F; Minnix M; Shively JE; Wong JYC; Wang X; Rockne RC
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680320
[TBL] [Abstract][Full Text] [Related]
5. Integrin α
Chen H; Zhao L; Fu K; Lin Q; Wen X; Jacobson O; Sun L; Wu H; Zhang X; Guo Z; Lin Q; Chen X
Theranostics; 2019; 9(25):7948-7960. PubMed ID: 31695808
[TBL] [Abstract][Full Text] [Related]
6. Solid-tumor radionuclide therapy dosimetry: new paradigms in view of tumor microenvironment and angiogenesis.
Zhu X; Palmer MR; Makrigiorgos GM; Kassis AI
Med Phys; 2010 Jun; 37(6):2974-84. PubMed ID: 20632610
[TBL] [Abstract][Full Text] [Related]
7. A Review on Tumor Control Probability (TCP) and Preclinical Dosimetry in Targeted Radionuclide Therapy (TRT).
Spoormans K; Crabbé M; Struelens L; De Saint-Hubert M; Koole M
Pharmaceutics; 2022 Sep; 14(10):. PubMed ID: 36297446
[TBL] [Abstract][Full Text] [Related]
8. Optimizing the Safety and Efficacy of Bio-Radiopharmaceuticals for Cancer Therapy.
Funeh CN; Bridoux J; Ertveldt T; De Groof TWM; Chigoho DM; Asiabi P; Covens P; D'Huyvetter M; Devoogdt N
Pharmaceutics; 2023 Apr; 15(5):. PubMed ID: 37242621
[TBL] [Abstract][Full Text] [Related]
9. Targeted α-Therapy Using
Ertveldt T; Krasniqi A; Ceuppens H; Puttemans J; Dekempeneer Y; Jonghe K; Mey W; Lecocq Q; Vlaeminck Y; Awad RM; Goyvaerts C; Veirman K; Morgenstern A; Bruchertseifer F; Keyaerts M; Devoogdt N; D'Huyvetter M; Breckpot K
J Nucl Med; 2023 May; 64(5):751-758. PubMed ID: 37055223
[TBL] [Abstract][Full Text] [Related]
10. Antitumor efficacy of
Potluri HK; Ferreira CA; Grudzinski J; Massey C; Aluicio-Sarduy E; Engle JW; Kwon O; Marsh IR; Bednarz BP; Hernandez R; Weichert JP; McNeel DG
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36002185
[TBL] [Abstract][Full Text] [Related]
11. Combined VLA-4-Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma.
Choi J; Beaino W; Fecek RJ; Fabian KPL; Laymon CM; Kurland BF; Storkus WJ; Anderson CJ
J Nucl Med; 2018 Dec; 59(12):1843-1849. PubMed ID: 29959213
[TBL] [Abstract][Full Text] [Related]
12. Targeted radionuclide therapy directed to the tumor phenotypes: A dosimetric approach using MC simulations.
Borbinha J; Ferreira P; Costa D; Vaz P; Di Maria S
Appl Radiat Isot; 2023 Feb; 192():110569. PubMed ID: 36436229
[TBL] [Abstract][Full Text] [Related]
13. [The Questionnaire Survey of Japanese Practice and Environment for Targeted Radionuclide Therapy in 2021].
Miyaji N; Yamashita K; Yoneyama H; Hanaoka K; Ukon N; Maeda T; Iimori T
Nihon Hoshasen Gijutsu Gakkai Zasshi; 2023 Mar; 79(3):262-270. PubMed ID: 36696976
[TBL] [Abstract][Full Text] [Related]
14. Combined Targeted Radiopharmaceutical Therapy and Immune Checkpoint Blockade: From Preclinical Advances to the Clinic.
Bellavia MC; Patel RB; Anderson CJ
J Nucl Med; 2022 Nov; 63(11):1636-1641. PubMed ID: 36215570
[TBL] [Abstract][Full Text] [Related]
15.
Shi X; Li Q; Zhang L; Hanyu M; Xie L; Hu K; Nagatsu K; Zhang C; Wu Z; Wang F; Zhang MR; Yang K; Zhu R
Bioconjug Chem; 2021 Aug; 32(8):1763-1772. PubMed ID: 34260853
[TBL] [Abstract][Full Text] [Related]
16. An Engineered Probiotic Platform for Cancer Epitope-Independent Targeted Radionuclide Therapy of Solid Tumors.
Siddiqui NA; Ventrola AJ; Hartman AR; Konare T; Kamble NS; Thomas SC; Madaan T; Kharofa J; Sertorio MG; Kotagiri N
Adv Healthc Mater; 2023 Jul; 12(19):e2202870. PubMed ID: 36913614
[TBL] [Abstract][Full Text] [Related]
17. Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade.
Patel RB; Hernandez R; Carlson P; Grudzinski J; Bates AM; Jagodinsky JC; Erbe A; Marsh IR; Arthur I; Aluicio-Sarduy E; Sriramaneni RN; Jin WJ; Massey C; Rakhmilevich AL; Vail D; Engle JW; Le T; Kim K; Bednarz B; Sondel PM; Weichert J; Morris ZS
Sci Transl Med; 2021 Jul; 13(602):. PubMed ID: 34261797
[TBL] [Abstract][Full Text] [Related]
18. Radiopharmaceutical Treatments for Cancer Therapy, Radionuclides Characteristics, Applications, and Challenges.
Salih S; Alkatheeri A; Alomaim W; Elliyanti A
Molecules; 2022 Aug; 27(16):. PubMed ID: 36014472
[TBL] [Abstract][Full Text] [Related]
19. Combination Therapy, a Promising Approach to Enhance the Efficacy of Radionuclide and Targeted Radionuclide Therapy of Prostate and Breast Cancer.
Damiana TST; Dalm SU
Pharmaceutics; 2021 May; 13(5):. PubMed ID: 34067215
[TBL] [Abstract][Full Text] [Related]
20. Fast beta-emitter Monte Carlo simulations and full patient dose calculations of targeted radionuclide therapy: introducing egs_mird.
Martinov MP; Opara C; Thomson RM; Lee TY
Med Phys; 2022 Sep; 49(9):6137-6149. PubMed ID: 35650012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
